• To estimate the budget impact of adding delayed-release dimethyl fumarate to a managed care formulary in the United States (US).
• The estimated budget impact of adding delayed-release dimethyl fumarate to the formulary was negative for the fi rst 5 years.
-In 2014, with a treatment share of 13.0%, the estimated budget decrease was 0.10% of the total annual costs for DMT-related and relapse treatment costs and a decrease of $0.006 per member per month (PMPM).
-In 2017, with a treatment share of 25.0%, the estimated budget decrease was also 0.10% of the total annual costs and a decrease of $0.007 PMPM (Table 4 ).
• Sensitivity analyses showed that the model was most sensitive to the acquisition costs of delayedrelease dimethyl fumarate ( Figure 2 ). 3 b Administration and monitoring costs for each DMT were estimated using resource use assumed to be needed to train and monitor self-administration for the injectable drugs and to administer infusions, as well as to monitor for effi cacy and safety through physician visits and laboratory tests as recommended in the product prescribing information; standard US unit costs were applied to the resource use estimates.
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Note: All costs reported in 2013/14 US dollars. • Drug costs included acquisition costs adjusted by copayments or coinsurance rates and dispensing fees, as well as administration and monitoring costs based on estimated resource use and US unit costs (Table 2 ).
Year
• A one-way sensitivity analysis was performed changing key input parameter values.
• Under model assumptions for treatment shares, adding delayed-release dimethyl fumarate to the MCO formulary would result in a small decrease in MCO costs for patients with relapsing forms of MS.
